With the development of therapies for metastatic colorectal cancer (CRC) targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, there has been significant effort to identify rational biomarkers of resistance or susceptibility. Initially, mutations in *KRAS* codons 12 and 13 were found to be predictive biomarkers of lack of response to anti-EGFR therapies ([@bib2]; [@bib21]; [@bib37]; [@bib5]), and more recently mutations in exons 3 and 4 of *KRAS* and in *NRAS* have also been identified as predictive of resistance to anti-EGFR therapies ([@bib13]). However, resistance to anti-EGFR therapy exists even among patients whose tumours are wild-type in *KRAS* and *NRAS*, demonstrating the need to find and characterise additional biomarkers of resistance.

The predictive impact of other mutations in signalling pathway components downstream of EGFR has been unclear. Among stage IV metastatic CRC patients treated with chemotherapy and cetuximab, *BRAF* mutation is associated with poor prognosis ([@bib12]; [@bib34]), but is not necessarily predictive of resistance to anti-EGFR therapy. A pooled analysis of two studies that randomised *KRAS* wild-type metastatic CRC patients to chemotherapy or chemotherapy plus cetuximab found that *BRAF* mutant patients had inferior overall survival (OS) than *BRAF* wild-type patients, but the addition of cetuximab was associated with non-significant trend towards improved survival in the *BRAF* mutant patients (HR 0.62, 95% CI 0.36--1.06, *P*=0.076) ([@bib6]). There are also conflicting results regarding the prognostic effect of *PIK3CA* mutations or PTEN expression loss on patients treated with anti-EGFR therapy ([@bib23]; [@bib25]; [@bib12]; [@bib34]; [@bib20]). The role of these mutations continues to undergo investigation.

A well-described biomarker associated with sensitivity to anti-EGFR therapy is increased tumour gene expression of *EREG* and *AREG*, which encode the EGFR ligands epiregulin and amphiregulin ([@bib22]; [@bib16]). *EREG* and *AREG* expression is inhibited by blockade of EGFR signalling and is stimulated by treatment with other EGFR ligands, and it has been hypothesised that higher expression of *EREG* and *AREG* may indicate tumour cell dependence on an autocrine EGFR-activating loop, and thus predict for increased susceptibility to anti-EGFR therapy ([@bib22]). However, mechanisms dictating varying levels of *EREG* or *AREG* expression remain unclear.

The site of the primary tumour also appears to be predictive of efficacy of anti-EGFR therapy. Clinical trials in patients with *KRAS* exon 2 wild-type metastatic CRC reveal that patients with left-sided colorectal primary tumours have superior progression-free survival (PFS) on treatment with cetuximab-based regimens compared with patients with right-sided primary tumours ([@bib38]; [@bib10]). Although the mechanism of this distinction is not defined, right-sided primary CRCs are known to have distinct pathobiology and characteristics, including higher rates of *BRAF* mutation, microsatellite instability (MSI-high), and high CpG island methylator phenotype (CIMP-high) ([@bib41]). CIMP-high tumours are marked by widespread DNA hypermethylation, which can epigenetically silence genes when occurring within promoter loci ([@bib40]). We sought to determine whether there was an association between global methylation status as assessed by CIMP status, the methylation status of CpG islands within the *AREG* and *EREG* promoters, the mRNA expression of *AREG* and *EREG*, and the site of the primary colorectal tumour in multiple independent data sets collected within the University of Texas MD Anderson Cancer Center (MDACC) and through The Cancer Genome Atlas (TCGA).

Materials and Methods
=====================

Patient cohorts and data analysis
---------------------------------

A cohort of 179 patients at MDACC with stages I--IV CRC provided informed consent for biomarker analyses on tumour tissue and retrospective analysis of patient records for research purposes, and the study was approved by the institutional review board. Eligible tumour specimens required at least 30% tumour cells on central review by a certified pathologist, and macrodissection of fresh frozen primary tumour tissue was performed. Gene expression analysis was performed using Agilent microarrays (Agilent Technologies, Santa Clara, CA, USA). RNA was isolated and assessed for quality, and RNA of adequate quality was amplified, labelled, and hybridised to the microarray. Data are expressed as *z*-scores. Methylation profiling was determined using the Illumina Infinium HumanMethylation450 BeadChip Kit (Illumina, San Diego, CA, USA), using bisulphite sequencing of methylated sites to determine methylation status at over 480 000 CpG sites covering 99% of Ref-seq genes.

Two additional cohorts of patients with stages II--IV colon or rectal adenocarcinoma were analysed from data generated by TCGA Research Network (<http://cancergenome.nih.gov/>): one cohort, 'TCGA27\' (*n*=218), had gene expression analysed by the Custom Agilent 244 K gene expression microarray (Agilent Technologies) and expressed as *z*-scores, and had methylation profiling performed using the Illumina Infinium HumanMethylation27 BeadChip as described ([@bib32]); and the second cohort, 'TCGA450\' (*n*=356), had gene expression analysed by RNA sequencing ([@bib32]) and expressed as log~2~-transformed values, and also had methylation profiling performed using the Illumina Infinium HumanMethylation450 BeadChip. In order to evaluate the correlation of CpG island methylation and gene expression, the TCGA pan-cancer data set was utilised ([@bib33]).

A final independent cohort of 440 stage IV CRC MDACC patients who had been heavily pretreated was enrolled on the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) protocol between August 2010 and October 2013 for screening and assignment to 10 individual phase I or II companion clinical trials based on testing of banked formalin-fixed, paraffin-embedded tumour tissue with gene sequencing, CIMP testing, and immunohistochemical staining. The patients in the ATTACC protocol provided informed consent for biomarker analyses on archived tumour tissue and retrospective analysis of patient records for research purposes, and the study was approved by the institutional review board. Of the 440 patients enrolled in ATTACC, 198 were *KRAS* exon 2 wild type by standard of care testing and were successfully tested for CIMP status. From the ATTACC specimens, bisulphite pyrosequencing of six well-defined, traditionally utilised CpG islands ([@bib35]) was performed, and specimens with ⩾40% methylation of CpG islands were deemed CIMP-high. The PCR primers used at MD Anderson for bisulphite pyrosequencing CpG islands in p14, p16, MLH1, MINT1, MINT2, and MINT31 are listed in [Supplementary Table 1A](#sup1){ref-type="supplementary-material"}.

Definition of CIMP status
-------------------------

CIMP status was determined from methylation arrays by using the following two methodologies: the first method was based on assessment of the methylation status of the six CpG islands used to determine CIMP status on clinical specimens in the ATTACC cohort; and the second method was based on clustering of methylation profiles using methodology paralleling that in TCGA ([@bib32]).

To extrapolate the CIMP status based on the six-locus clinical panel from the Illumina Infinium HumanMethylation450 BeadChip results, the PCR primers for the bisulphite-treated sequences for p14, p16, MLH1, MINT1, MINT2, and MINT31 were obtained. A search for the corresponding sequence within the human genome was undertaken using BiSearch (<http://bisearch.enzim.hu/>) ([@bib36]; [@bib3]), and the identity of the sequence was verified by ensuring that the sequencing primer was located within the identified region. To identify the corresponding nucleotide location within GRCh37, NCBI Blast was performed ([Supplementary Table 1B](#sup1){ref-type="supplementary-material"}). Subsequently, the CpG islands from the Illumina Infinium HumanMethylation450 array that were located within the primer regions were determined, and 1--2 CpG islands within the PCR-amplified regions were found for the MLH1, MINT2, and MINT31 primers. For the MINT1, p14, and p16 primers, no CpG islands on the panel were found within the amplified regions, although 1--2 CpG islands located \<300 nucleotides away for each of the primer pairs were found ([Supplementary Table 1C](#sup1){ref-type="supplementary-material"}). The beta-value of each of these CpG islands was transformed to an M-value ([@bib14]), and the distribution of M-values for each data set was plotted and found to be bimodal. For each CpG island, a threshold was determined at the point between the two modes to dichotomise the methylation status in the MDACC data. This threshold was applied to the M-value transformations of the TCGA data and was found to also reflect the point between the two modes ([Supplementary Table 2A and B](#sup1){ref-type="supplementary-material"}). Then, a voting scheme mirroring the clinical CIMP panel was enacted to determine CIMP status (CIMP-high represents \>40% or ⩾3/6 markers).

For the TCGA samples assayed with the Illumina Infinium HumanMethylation27 BeadChip instead of the larger Illumina Infinium HumanMethylation450 BeadChip, it was not possible to align the clinical panel with existing CpG island probes. Instead, a clustering method of methylation profiles was used, following the methods described in the TCGA manuscript ([@bib32]).

Cell line data sets
-------------------

To determine the effect of hypomethylating agents azacitidine and decitabine on methylation of specific CpG island promoters, raw experimental data were obtained from ArrayExpress database ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress)) using accession number E-MTAB-417. In this study, HCT116 colon cancer cells were treated with 1 *μ*M azacitidine or decitabine for 24 h. Subsequently, the Illumina Infinium HumanMethylation27 BeadChip was used to determine methylation status ([@bib15]).

To determine the effect of the hypomethylating agent azacitidine on expression of *EREG* and *AREG*, experimental data was obtained from the Gene Expression Omnibus (<http://www.ncbi.nlm.nih.gov/geo/>) using accession number GSE57341. In this study, a panel of 14 CRC cell lines was treated with 500 nM of azacitidine for 72 h. Cells were harvested at 1, 3, 7, 10, 14, 21, or 28 days, and expression was assayed using the Agilent 44K Expression Array ([@bib24]).

Statistical analysis
--------------------

Gene expression microarray data were provided as *z*-scores. RNA-seq data were provided as raw values that were base 2 logarithmically transformed for statistical analysis. To identify association between clinical characteristics and expression or methylation levels, the Mann--Whitney *U*-test was utilised if variables were dichotomous, or the Kruskal--Wallis test was utilised if variables had \>2 possible values. To perform survival analysis with PFS, the Kaplan--Meier method was used and significance testing was performed using the log-rank test. Additional univariate and multivariate Cox regression analyses were performed using IBM SPSS Statistics version 21 (Armonk, NY, USA). In addition, integrated Bayesian analysis of high-dimensional multiplatform genomics (iBAG) ([@bib39]) data was performed using the nonlinear approach ([@bib17]) to determine the percent of variability in expression that is explained by methylation. This method involved fitting an additive regression model in which expression was regressed on methylation and copy number as additive nonparametric predictors, with residual error representing variability in expression not explained by methylation or copy number, that is, explained by some other upstream regulator. After model fitting, percent variability explained by methylation, copy number, and other causes were estimated through the corresponding coefficients of determination.

For the MDACC ATTACC cohort, to determine associations with PFS and OS, multiple imputation methodology was used, with predictor variables including age, sex, CIMP-high *vs* low/none, right- *vs* left-sided primary tumours, duration of first EGFR regimen, progression status, prior bevacizumab, presence or absence of additional cytotoxic chemotherapy, PTEN status, *PIK3CA* mutation status, *BRAF* mutation status, *NRAS* mutation status, and number of prior chemotherapy regimens. Any missing values were addressed using an assumption of missing at random and multivariate normality using the MCMC method in SPSS to create 20 imputed data sets. Subsequently, Cox proportional hazards models were used to perform univariate and multivariate regression analyses for PFS with the first anti-EGFR regimen or OS.

Results
=======

*EREG* and *AREG* expression are strongly inversely associated with methylation of loci within the promoters of *EREG* and *AREG*
---------------------------------------------------------------------------------------------------------------------------------

A cohort of 179 MDACC patients with CRC had primary tumour specimens assayed for *EREG* and *AREG* methylation and expression. Characteristics of the patient cohort are described in [Supplementary Table 3](#sup1){ref-type="supplementary-material"}. Eight out of nine CpG islands located within the *EREG* gene promoter or body were significantly inversely associated with expression, as were four out of five CpG islands located within the *AREG* gene and promoter ([Supplementary Table 4A and B](#sup1){ref-type="supplementary-material"}). The strongest correlation with *EREG* expression was with the CpG island cg19308222 (*ρ*=−0.726, *P*\<10^−6^; [Figure 1A](#fig1){ref-type="fig"}). The strongest correlation with *AREG* expression was with the CpG islands cg26611070 (*ρ*=−0.520, *P*\<10^−6^) and cg022334660 (*ρ*=−0.501, *P*\<10^−6^; [Supplementary Figure 1a and b](#sup1){ref-type="supplementary-material"}). These findings demonstrate that there is a significant inverse association between DNA methylation and expression of *EREG* and *AREG*, and identify promoter methylation as a significant regulatory mechanism of expression of *EREG* and *AREG*.

To confirm these findings, the association of *EREG* and *AREG* methylation and expression was determined in two independent cohorts of colon and rectal adenocarcinoma cancer specimens from the TCGA. In the TCGA450 cohort (*n*=356; [Supplementary Tables 4A and B and 5](#sup1){ref-type="supplementary-material"}), the strongest correlation with *EREG* expression was again with the CpG island cg19308222 (*ρ*=−0.671, *P*\<10^−6^; [Figure 1B](#fig1){ref-type="fig"}), and the strongest correlation with *AREG* expression was again with the CpG island cg02334660 (*ρ*=−0.457, *P*\<10^−6^; [Supplementary Figure 1c and d](#sup1){ref-type="supplementary-material"}). In the TCGA27 cohort (*n*=218; [Supplementary Table 6](#sup1){ref-type="supplementary-material"}), strong inverse correlation was again observed between *EREG* expression and cg19308222 (*ρ*=−0.659, *P*\<10^−6^; [Figure 1C](#fig1){ref-type="fig"}). Because the panel of CpG islands tested for methylation was smaller in this array, there were no CpG islands tested within the *AREG* promoter.

To put this strong negative correlation in context, among colon adenocarcinoma specimens in the TCGA, the inverse correlation between methylation at cg19308222 and *EREG* expression was the 219th out of 18 945 most-negative correlation (top 1.2%) and between methylation at cg02334660 and *AREG* expression was the 1801th out of 18 945 (top 9.5%) among methylation/gene expression pairs ([@bib8]). Similarly, among rectal adenocarcinoma specimens in the TCGA, the inverse correlation between methylation at cg19308222 and *EREG* expression was the 155th out of 19 209 most-negative correlation (top 0.8%), and the inverse correlation between methylation at cg26611070 and *AREG* expression was the 1686th out of 19 209 most-negative correlation (top 8.8%) among methylation/gene expression pairs ([@bib7]).

iBAG analysis
-------------

Additional analysis was completed to determine the extent to which variation in expression of *EREG* and *AREG* was attributable to methylation, compared with copy number variation or other unspecified upstream regulators, using iBAG ([@bib39]). In the MDACC cohort, 64.5% of *EREG* expression variation was explained by methylation of cg19308222, compared with 2.9% by copy number variation and 32.7% from other causes. In *AREG*, if considering cg02334660 alone, 33.8% of expression was explainable by variation in methylation, compared with 0.5% by copy number variation and 65.7% by other causes. If considering cg2661070 alone, 34.8% of expression was explained by variation in methylation, compared with 0.6% by copy number variation and 64.6% by other causes. In the TCGA27 cohort, 57.5% of *EREG* expression variation was explained by methylation of the cg19308222 locus, compared with 0.9% from copy number variation and 41.7% from other causes. The variation for *AREG* could not be determined as there was no *AREG* methylation locus in the Illumina Infinium 27K panel.

By comparison, in a large set of 799 genes analysed by iBAG in two CRC cohorts, both the TCGA27 cohort and the MDACC cohort, we found the median percent of expression explained by variation in methylation was 5.78%. Only 5 of these 799 genes (0.63%) had \>60% of expression variability explained by methylation, placing *EREG* within the top 1% of genes whose expression was predominantly modulated by methylation.

Demethylating agents decrease methylation levels and increase expression of *EREG*
----------------------------------------------------------------------------------

In order to evaluate whether methylation modulates *EREG* expression, we utilised RNA arrays and Illumina Infinium HumanMethylation27 BeadChip data sets for CRC cell lines treated with azacitidine and decitabine. *EREG* methylation at cg19308222 was significantly reduced by treatment with either azacitidine or decitabine ([Figure 1D](#fig1){ref-type="fig"}). In contrast, the *EREG* associated CpG site cg04941721 was not altered with either agent, consistent with the limited correlation of this site with *EREG* expression. No CpG probes for *AREG* are present on the Illumina 27K array, limiting evaluation of this target. Expression of *EREG* was evaluated at various time points after 72 h of treatment with azacitidine in a panel of 14 CRC cell lines, demonstrating a time-dependent increase in expression of *EREG*, which was not seen in *AREG* ([Figure 1E and F](#fig1){ref-type="fig"}).

Right-sided primary, CIMP-high, MSI-high, and BRAF-mutated cancers are associated with higher levels of gene methylation and lower levels of expression of *EREG* and *AREG*
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, we examined whether additional clinical and pathological characteristics of CRC were associated with significant differences in methylation and expression of *AREG* and *EREG*. In the MDACC cohort, right-sided primary tumour, MSI-high status, *BRAF* V600E mutant status, and mucinous histology were all associated with significantly lower levels of *AREG* and *EREG* expression, and significantly higher levels of methylation of the *AREG* loci cg02334660 and cg26611070, and the *EREG* locus cg19308222 ([Table 1](#tbl1){ref-type="table"} and [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}). CIMP was defined by one of two different methods, and CIMP-high status by either method was associated with significantly lower *AREG* and *EREG* expression, and significantly higher methylation of *EREG* cg19308222 ([Table 1](#tbl1){ref-type="table"} and [Figure 2A and B](#fig2){ref-type="fig"}). In the TCGA450 cohort, similar to the MDACC results, MSI-high status, *BRAF* mutant status, mucinous histology, and right-sided primary tumour were significantly associated with lower levels of *AREG* and *EREG* expression, and with higher levels of methylation at the *AREG* loci cg02334660 and cg26611070, and the *EREG* locus cg19308222 ([Table 2](#tbl2){ref-type="table"} and [Supplementary Figure 4](#sup1){ref-type="supplementary-material"}). CIMP-high status, determined by clinical method, was again associated with lower *AREG* and *EREG* expression, and with higher methylation of the *AREG* and *EREG* loci ([Figure 2C and D](#fig2){ref-type="fig"}). In the TCGA27 cohort, MSI-high status, *BRAF* mutant status, mucinous histology, and right-sided primary tumour were all again associated with significantly lower levels of *AREG* and *EREG* expression, and significantly higher levels of methylation of the *EREG* locus cg19308222 ([Supplementary Table 7](#sup1){ref-type="supplementary-material"}). In addition, CIMP-high status, as assessed by clustering, was also significantly associated with lower levels of *AREG* and *EREG* expression, and higher levels of *EREG* methylation at cg19308222.

Among the subgroup of 84 patients in the MDACC cohort known to be wild-type both in *BRAF* codon 600 and in *KRAS* codons 12 and 13, right-sided primary tumour location remained significantly associated with lower *AREG* and *EREG* expression, and higher methylation of the *AREG* loci cg02334660 and cg26611070, and the *EREG* locus cg19308222 ([Supplementary Table 8](#sup1){ref-type="supplementary-material"} and [Supplementary Figure 3](#sup1){ref-type="supplementary-material"}). In this subgroup, CIMP-high status as determined by the clinical method was significantly associated with higher methylation levels of *EREG* cg19308222 and was non-significantly associated with lower *EREG* expression. Similarly, in the subgroup of 163 patients in the TCGA450 cohort who were wild-type both in *BRAF* and in *KRAS* codons 12 and 13, MSI-high status, mucinous histology, and right-sided primary tumour remained significantly associated with lower *AREG* and *EREG* expression, and higher levels of methylation at the *AREG* and *EREG* loci. CIMP-high status remained significantly associated with lower *EREG* expression and higher levels of methylation at the *AREG* and *EREG* loci.

Finally, among the subgroup of 134 patients in the TCGA450 cohort who were wild-type in *BRAF*, *KRAS* exons 2--4, and *NRAS*, MSI-high status, mucinous histology, right-sided primary tumour, and CIMP-high status remained significantly associated with lower *AREG* and *EREG* expression, and higher levels of methylation at the *AREG* and *EREG* loci ([Supplementary Table 9](#sup1){ref-type="supplementary-material"} and [Supplementary Figure 5](#sup1){ref-type="supplementary-material"}). Similarly, among the 100 patients in the TCGA27 cohort who were wild-type in *BRAF*, *KRAS*, and *NRAS*, a significant association with lower *EREG* and *AREG* expression, and higher *EREG* cg19308222 methylation remained with CIMP-high status, right-sided primary tumour, and MSI-high status ([Supplementary Table 7](#sup1){ref-type="supplementary-material"}).

CIMP-high status is associated with inferior PFS to anti-EGFR therapy in KRAS wild-type patients
------------------------------------------------------------------------------------------------

An independent cohort of 198 patients with *KRAS* wild-type metastatic CRC enrolled in the ATTACC protocol at MDACC was successfully tested for CIMP status ([Supplementary Table 10](#sup1){ref-type="supplementary-material"}). Of this group, 173 patients had previously been treated with an anti-EGFR therapy, and PFS with the first anti-EGFR regimen was retrospectively determined in 167 patients. Of this group, 26.3% (44/167) patients were CIMP-high. Compared with the CIMP-low/none group, the CIMP-high group was significantly more likely to have right-sided primary tumour (45.5% *vs* 23.6%, *P*=0.011), MSI-high status (18.5% *vs* 1.6%, *P*=0.009), *BRAF* mutation (42.9% *vs* 6.9%, *P*\<0.0001), and male sex (77.3% *vs* 60.2%, *P*=0.045).

Kaplan--Meier analysis found that among the entire cohort of 167 *KRAS* wild-type patients, inferior PFS with the first anti-EGFR therapy regimen was significantly associated with CIMP-high status (median PFS 4.0 *vs* 6.5 mo, *P*\<0.001), *BRAF* mutation (median PFS 2.8 *vs* 6.5 mo, *P*=0.004), *NRAS* mutation (median PFS 4.4 *vs* 7.2 mo, *P*=0.006), and right-sided primary tumour (median PFS 4.7 *vs* 6.5 mo, *P*=0.040) ([Figure 2E and F](#fig2){ref-type="fig"} and [Supplementary Figure 6a](#sup1){ref-type="supplementary-material"}). These findings were recapitulated on univariate analysis by Cox proportional hazards regression analysis. On multivariate Cox regression analysis by multiple imputations, *NRAS* mutation (HR 2.27, 95% CI 1.25--4.13, *P*=0.007), *BRAF* mutation (HR 2.50, 95% CI 1.22--5.13, *P*=0.012), and CIMP-high status (HR 2.00, 95% CI 1.11--3.64, *P*=0.022) remained significant. Right-sided primary tumour was not significant (HR 1.43, 95% CI 0.86--2.36, *P*=0.167) ([Table 3](#tbl3){ref-type="table"}). In the subgroup with *BRAF* and *NRAS* wild-type disease, inferior PFS with the first anti-EGFR regimen remained significantly associated with CIMP-high status (median PFS 5.6 *vs* 9.0 mo, *P*=0.023) and trended with right-sided primary tumour (median PFS 5.6 *vs* 9.0 mo, *P*=0.053) on Kaplan--Meier analysis ([Figure 2G](#fig2){ref-type="fig"} and [Supplementary Figure 6b](#sup1){ref-type="supplementary-material"}).

Notably, on univariate analysis of OS among the 198 patients, with 162 events, CIMP-high status (HR 1.53, 95% CI 1.08--2.16), right-sided primary tumour (HR 1.45, 95% CI 1.04--2.01), *BRAF* mutation (HR 2.46, 95% CI 1.61--3.75), and *NRAS* mutation (HR 1.70, 95% CI 1.03--2.81) were significantly associated with inferior survival. However, neither CIMP-high status nor right-sided primary tumour were significantly associated with OS on multivariate analysis among the entire cohort or on univariate analysis among the subgroup of 109 patients known to be wild-type in *BRAF* and *NRAS*.

Discussion
==========

Our study is one of the first to identify CIMP status, and more specifically methylation of loci within the *EREG* and *AREG* promoters, as a determinant of *EREG* and *AREG* expression levels and a prognostic biomarker with regards to PFS upon treatment with anti-EGFR therapy in patients with metastatic CRC. Given the association we and others have observed between *EREG* levels and the site of primary tumour, this provides additional explanation for the clinical differences observed in right- *vs* left-sided primary tumours. Although our data are retrospective and are not derived from clinical trials, the use of multiple independent data sets available through the TCGA to validate our findings is a strength of our study.

Although methylation of CpG islands within gene promoters is generally known to be associated with downregulation of expression, it remains unclear which methylated loci are most important in driving differential expression. Although the TCGA Pan-Cancer project has identified for each gene the single CpG island most inversely correlated with expression, our results extended these results specifically to CRCs. For *EREG*, we found that the CpG island cg19308222, which was most strongly inversely correlated with expression in the Pan-Cancer project, was again the most inversely correlated CpG island in CRC. However, for *AREG*, we found that the CpG islands cg02334660 and cg26611070 had the strongest inverse correlation with expression in CRC, while in the Pan-Cancer project, cg03244277 had the strongest inverse correlation. Indeed, both cg02334660 and cg26611070 are located within the body of the *AREG* gene. Although gene-body methylation is thought to be associated with increased expression ([@bib42]), body methylation may conversely function to repress activation of intragenic promoters and functions in a tissue-specific context ([@bib27]; [@bib18]). The tissue-specific effects of methylation at specific loci in specific genes requires further investigation, as this may explain the differences in which locus was selected as the most anti-correlated with expression.

The significant contribution of *EREG* and *AREG* methylation on gene expression has not been previously well described. A small *in vitro* study of gastric cancer cell lines revealed inverse correlation between *EREG* promoter methylation and expression ([@bib43]). Indeed, iBAG analysis demonstrated that ∼57--65% of variation of expression in *EREG* was attributable to methylation of cg19308222, and 33--35% of variation of expression in *AREG* was attributable to methylation of the *AREG* loci cg02334660 or cg2661070. Furthermore, treatment of CRC cell lines with demethylating agents indeed resulted in decreased methylation at the cg19308222 locus and increased expression of *EREG*. This provides the strongest evidence to date that methylation of these important EGFR ligands is a significant likely mechanism of regulation of expression, and also suggests that this mechanism can be manipulated by treatment with hypomethylating agents.

Several studies have already established that high expression of *EREG* and *AREG* is associated with improved outcomes with anti-EGFR therapy in refractory metastatic CRC. A study of tumours from 110 metastatic CRC patients treated with cetuximab found that high *EREG* or *AREG* expression was associated with longer PFS (HR 0.47, *P*=0.0002; and HR 0.44, *P*\<0.0001, respectively) ([@bib22]), although it was unclear whether there was an interaction of *EREG* and *AREG* expression level with *KRAS* or *BRAF* mutation status. Another study in 121 irinotecan-refractory *KRAS* wild-type metastatic CRC patients who received anti-EGFR therapy on clinical trials found that *EREG* and *AREG* expression was significantly associated with response rate, disease control, PFS, and OS with anti-EGFR therapy, with the predictive value of *EREG* expression superior to that of *AREG* expression ([@bib16]). Analysis from the CO.17 trial of cetuximab in patients with refractory metastatic CRC found cetuximab had a larger effect in improvement of OS and PFS in *KRAS* wild-type and *EREG* expression-high patients ([@bib19]). Similarly, results from the PICCOLO trial of second-line panitumumab and irinotecan in metastatic CRC found significant improvement in PFS in patients with either *EREG* or *AREG* expression in the highest tertile ([@bib30]). Finally, a retrospective evaluation of expression of 110 candidate genes from 144 primary tumours of *KRAS* wild-type refractory metastatic CRC patients found that high *EREG* and *AREG* expression was strongly associated with improved PFS and disease control rate with cetuximab ([@bib4]). In contrast, two first-line studies failed to demonstrate that *EREG* or *AREG* expression is predictive of benefit with cetuximab when combined with multi-agent chemotherapy backbones ([@bib1]; [@bib11]). Moreover, these studies did not further describe additional clinical and pathological variables that we now know may have impacted *EREG* and *AREG* expression.

Additional data reveal that patients whose tumours have high *EREG* and *AREG* expression are more likely to have clinical and tumour biological characteristics similar to those we found. Indeed, data from 952/1630 samples from the randomised phase III COIN (addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced CRC) trial showed that high expression of *EREG* and *AREG* was significantly associated with wild-type *KRAS*, wild-type *BRAF*, left-sided primary colon tumour, and microsatellite stable disease ([@bib1]). An independent study also found that left-sided primary colon carcinomas were more likely to have epiregulin overexpression ([@bib28]). Moreover, data from 331/696 samples from the randomised PICCOLO (Panitumumab, irinotecan, and ciclosporin in CRC) trial in second-line treatment of metastatic CRC similarly found that high expression of *EREG* and *AREG* was associated with wild-type *BRAF* and left-sided primary colon tumour ([@bib30]).

Also, multiple trials showed that patients with *KRAS* wild-type left-sided CRC have improved outcomes upon treatment with cetuximab than those with right-sided CRC. In the AIO KRK-0104 trial, 146 patients were randomised to receive first-line CAPOX with cetuximab or CAPIRI (capecitabine/irinotecan) with cetuximab. In this trial, 95/146 patients had *KRAS* codon 12 and 13 wild-type tumour, with 68 left-sided and 27 right-sided primary tumours. Patients with left-sided *KRAS* exon 2 wild-type cancers had superior OS (HR 0.63, *P*=0.016) and PFS (HR 0.67, *P*=0.02) than patients with right-sided tumours. In patients with *KRAS*/*BRAF* wild-type tumours (*n*=79), median PFS was 8.2 *vs* 5.9 mo (HR 0.81, *P*=0.47) and median OS was 27.3 *vs* 16.2 mo (HR 0.60, *P*=0.11; [@bib38]). In the CO.17 study, 399 patients with metastatic CRC were randomised to receive cetuximab or best supportive care. In the cohort of patients with *KRAS* exon 2 wild-type status, there was a significant interaction between site of primary tumour and PFS benefit with cetuximab (for left-sided tumours, HR 0.28 and *P*\<0.0001; for right-sided tumours, HR 0.73 and *P*=0.26), with predictive effect interaction term (*P*=0.002) ([@bib9]; [@bib10]).

Notably, although CIMP-high status and right-sided primary CRC were both associated with significantly inferior OS on univariate analysis, neither remained significant after adjusting for *NRAS* and *BRAF* status. As CIMP-high status remained significantly associated with PFS with anti-EGFR therapy after adjusting for these variables, this suggests that the inferior anti-EGFR PFS of CIMP-high patients is not solely due to an overall inferior prognosis, at least among the *KRAS*/*NRAS*/*BRAF* wild-type subpopulation. Indeed, several studies have noted inferior overall prognosis among patients with low *EREG*/*AREG* expression ([@bib29]; [@bib31]) or right-sided primary CRC ([@bib26]). These studies are variable in whether they included only patients with *KRAS* wild-type tumours, whether they limited analysis to patients with anti-EGFR therapy only, and whether *EREG* and *AREG* were treated as a continuous or categorical variable and how any cut points were defined. Furthermore, none included CIMP status in their multivariable analyses. Furthermore, recent data from the PICCOLO study show that although high *EREG* and *AREG* levels were associated with improved OS among all patients and among the RAS wild-type subgroup, neither was significantly associated with OS among the RAS and *BRAF* wild-type subgroup. In that study, site of primary tumour was not associated with PFS or OS ([@bib30]). Additional studies to confirm these findings in prospectively collected data will be important in determining the predictive *vs* prognostic role of these variables.

Previously, there had not been data for a plausible biological explanation for the differential outcomes of left- and right-sided primary CRCs with cetuximab-based treatment, but our findings provide evidence that variation in *EREG* and *AREG* methylation, and expression contribute to these differences ([Figure 3](#fig3){ref-type="fig"}). Although there is ample existing evidence of the association of right-sided primary cancers with CIMP-high status, our analysis provides a novel association between right-sided and CIMP-high CRCs with increased methylation specifically of the critical CpG islands within *EREG* and *AREG* that have the strongest inverse association with *EREG* and *AREG* expression. Accordingly, there is also an association with low *EREG* and *AREG* expression. Several studies have corroborated that low *EREG* and *AREG* expression are associated with inferior outcomes with cetuximab therapy, even if there is conflicting evidence whether *EREG* and *AREG* are predictive or merely prognostic. Nevertheless, these data are consistent with our retrospective analysis showing that CIMP-high status is associated with inferior PFS with anti-EGFR-including therapy.

Although our findings unify disparate observations and associations between location of primary tumour, expression of *EREG* and *AREG*, and differential responses to cetuximab, they are based on retrospective analysis of several different data sets and thus cannot ascertain causality. Prospective incorporation of these variables into the analysis of adequately powered future randomised controlled trials of anti-EGFR therapies in first-line and refractory metastatic CRC will be necessary to determine whether CIMP status and methylation level of *EREG* and *AREG* are truly predictive of response. Further investigation is warranted into whether differential methylation and expression of additional genes in CIMP-high patients contribute to resistance to anti-EGFR therapy.

This research was supported by American Society of Clinical Oncology Conquer Cancer Foundation Young Investigator Awards individually granted to MSL and VKM; NIH R01 CA160736 (to VB); NCI Cancer Center Support Grant (CCSG) P30 CA016672 (to VB, WW, and SK); NIH R01 CA172670 (to SK), and NIH R01 CA184843 (to SK).

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.

The authors declare no conflict of interest.

Supplementary Material {#sup1}
======================

###### 

Click here for additional data file.

![***EREG* methylation is inversely associated with expression, and is modulated by hypomethylating agents.** (**A--C**) Scatter plots of methylation β-value at the *EREG* CpG island cg19308222 compared with *EREG* expression in the (**A**) MDACC cohort (*n*=179), (**B**) TCGA450 cohort (*n*=356), or (**C**) TCGA27 cohort (*n*=218). (**D**) Methylation at cg19308222 after treatment with 1 *μ*M azacitidine or decitabine for 24 h. (**E** and **F**) Expression of *EREG* (A_23_P41344), but not *AREG* (A_23_P249071), is increased after treatment with 500 nM azacitidine for 72 h and cell harvesting after the indicated duration. \**P*\<0.05 compared with control.](bjc201687f1){#fig1}

![**CIMP status is associated with *EREG* methylation and expression, and with the duration of progression-free survival with anti-EGFR therapy.** (**A** and **B**) BLiP plots comparing (**A**) *z*-score of *EREG* expression and (**B**) methylation levels at cg19308222 in CIMP-high *vs* low/none as determined by clinical method in the MDACC cohort (*n*=179). (**C** and **D**) BLiP plots comparing (**C**) log~2~-transformed *EREG* expression and (**D**) methylation levels at cg19308222 in CIMP-high *vs* low/none as determined by clinical method in the TCGA450 cohort (*n*=356). (**E**--**G**) Kaplan--Meier curves of PFS with first anti-EGFR regimen among patients in the MDACC ATTACC cohort (**E**) grouped by *BRAF* and *NRAS* mutation status (for *NRAS* mutant *vs BRAF*/*NRAS* WT, *P*=0.0007; for *BRAF* mutant *vs BRAF*/*NRAS* WT, *P*=0.0003); (**F**) grouped by CIMP-high *vs* CIMP-low/none status among all patients in the cohort (*n*=167); or (**G**) grouped by CIMP-high *vs* CIMP-low/none status among the subgroup of patients known to be wild type in *BRAF* and *NRAS* (*n*=88).](bjc201687f2){#fig2}

![**Left- and right-sided primary CRCs have distinct pathobiology, with different rates of CIMP, and contrasting levels of methylation and gene expression of *EREG* and *AREG*, providing a unifying explanation for differences in outcomes with anti-EGFR therapy like cetuximab.**](bjc201687f3){#fig3}

###### Univariate analyses of clinical and pathological characteristics from the MDACC cohort (*n*=179)

                                   ***AREG*** **expression (*****z*****-score)**   ***EREG*** **expression (*****z*****-score)**   ***AREG*** **methylation cg02334660**   ***AREG*** **methylation cg26611070**   ***EREG*** **methylation cg19308222**                                      
  ------------------------- ----- ----------------------------------------------- ----------------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------- ------- --------- ------- ---------
  CIMP status (clinical)                                                                               0.005                                                                              \<0.001                                                           0.243             0.182            \<0.001
   High                      52                       −0.144                                                                                      −0.383                                                                           0.459                             0.477             0.427       
   Low/none                  127                       0.142                                                                                       0.187                                                                           0.435                             0.449             0.207       
  CIMP status (cluster)                                                                                0.001                                                                              \<0.001                                                           0.034             0.033            \<0.001
   High                      35                       −0.255                                                                                      −0.393                                                                           0.487                             0.519             0.452       
   Low/none                  143                       0.134                                                                                       0.153                                                                           0.429                             0.446             0.225       
  Mucinous                                                                                             0.005                                                                              \<0.001                                                           0.004             0.003            \<0.001
   Yes                       29                       −0.185                                                                                      −0.698                                                                           0.517                             0.547             0.423       
   No                        130                       0.137                                                                                       0.144                                                                           0.425                             0.44              0.23        
  Location of primary                                                                                 \<0.001                                                                             \<0.001                                                          \<0.001           \<0.001           \<0.001
   Right-sided               82                        −0.12                                                                                      −0.258                                                                           0.489                             0.518             0.331       
   Left-sided                77                        0.193                                                                                       0.252                                                                           0.395                             0.413              0.2        
  MSI status                                                                                          \<0.001                                                                              0.002                                                           \<0.001           \<0.001            0.001
   MSI-high                  22                       −0.293                                                                                      −0.478                                                                           0.646                             0.703             0.453       
   MSS                       93                        0.157                                                                                       0.172                                                                           0.408                             0.433             0.229       
  *BRAF* V600E                                                                                        \<0.001                                                                             \<0.001                                                          \<0.001           \<0.001           \<0.001
   Mutant                    19                       −0.275                                                                                      −0.775                                                                           0.542                             0.556             0.452       
   Wild-type                 133                       0.154                                                                                       0.172                                                                           0.42                              0.442             0.229       
  *KRAS* codon 12/13                                                                                   0.002                                                                               0.006                                                            0.87              0.998             0.051
   Mutant                    49                       −0.061                                                                                      −0.196                                                                           0.448                             0.457             0.298       
   Wild-type                 103                       0.163                                                                                       0.189                                                                           0.423                             0.453             0.232       
  *PIK3CA*                                                                                             0.46                                                                                0.584                                                            0.056             0.089             0.235
   Mutant                    21                        0.088                                                                                       0.138                                                                           0.482                             0.509             0.282       
   Wild-type                 131                       0.064                                                                                       0.079                                                                           0.423                             0.444             0.241       
  Stage                                                                                                0.952                                                                                0.6                                                             0.281             0.293             0.905
   2                         74                        0.052                                                                                       0.108                                                                           0.466                             0.47              0.244       
   3                         78                        0.095                                                                                       0.012                                                                           0.426                             0.443             0.268       
   4                          7                       −0.016                                                                                      −0.317                                                                           0.399                             0.428             0.229       
  Lymphovascular invasion                                                                              0.112                                                                               0.074                                                            0.168             0.173             0.147
   Yes                       104                       0.117                                                                                       0.123                                                                           0.416                             0.442             0.248       
   No                        55                        −0.03                                                                                      −0.196                                                                           0.472                             0.492             0.313       

Abbreviations: CIMP=CpG island methylator phenotype; MDACC=MD Anderson Cancer Center; MSI=microsatellite instability.

*P*-values obtained by Mann--Whitney *U-*test if variable is dichotomous or Kruskal--Wallis test if \>2 variables.

###### Univariate analyses of clinical and pathological characteristics from the TCGA450 cohort (*n*=356)

                                   ***AREG*** **expression (log**~**2**~)   ***EREG*** **expression (log**~**2**~)   ***AREG*** **methylation cg02334660**   ***AREG*** **methylation cg26611070**   ***EREG*** **methylation cg19308222**                                        
  ------------------------- ----- ---------------------------------------- ---------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- --------- -------- --------- -------- ---------
  CIMP status                                                                              \<0.001                                                                          \<0.001                                                          \<0.001            \<0.001            \<0.001
   High                      97                    9.474                                                                             7.657                                                                           0.541                             0.572              0.605        
   Low/none                  259                   10.137                                                                           10.096                                                                           0.432                             0.452              0.211        
  Location of primary                                                                      \<0.001                                                                          \<0.001                                                          \<0.001            \<0.001            \<0.001
   Right-sided               169                   9.597                                                                             8.408                                                                           0.508                             0.5339             0.4466       
   Left-sided                179                   10.299                                                                           10.346                                                                          0.4346                             0.4481             0.1859       
  MSI status                                                                               \<0.001                                                                          \<0.001                                                          \<0.001            \<0.001            \<0.001
   MSI-high                  52                    8.281                                                                             5.135                                                                          0.7399                             0.7882             0.6063       
   MSS                       302                   10.139                                                                           10.059                                                                          0.4377                             0.4579             0.2279       
  *BRAF* V600E                                                                             \<0.001                                                                          \<0.001                                                          \<0.001            \<0.001            \<0.001
   Mutant                    26                    8.175                                                                             4.696                                                                          0.6727                             0.6946             0.6581       
   Wild-type                 262                   10.147                                                                           10.104                                                                          0.4536                             0.4689             0.2331       
  *KRAS* codon 12/13                                                                        0.331                                                                            0.313                                                            0.862              0.854              0.133
   Mutant                    99                    9.714                                                                             9.174                                                                           0.475                             0.492              0.338        
   Wild-type                 189                   10.136                                                                           10.034                                                                           0.467                             0.479              0.239        
  *KRAS* exons 2--4                                                                         0.249                                                                            0.206                                                            0.374              0.401              0.335
   Mutant                    114                   9.728                                                                             9.005                                                                           0.441                              0.47              0.324        
   Wild-type                 174                   10.16                                                                            10.146                                                                           0.473                              0.49              0.239        
  *NRAS*                                                                                    0.725                                                                            0.763                                                            0.153               0.2               0.618
   Mutant                    15                    10.066                                                                           10.349                                                                          0.4371                             0.4556             0.2851       
   Wild-type                 273                   10.063                                                                            9.661                                                                          0.4747                             0.4923             0.2503       
  *PIK3CA*                                                                                  0.566                                                                            0.94                                                             0.834              0.714              0.458
   Mutant                    65                    9.805                                                                             9.621                                                                          0.4812                             0.4923             0.3232       
   Wild-type                 223                   10.074                                                                            9.757                                                                          0.4621                             0.4844             0.2464       
  Stage                                                                                     0.575                                                                            0.423                                                            0.532              0.497              0.372
   1                         53                    9.874                                                                             8.685                                                                           0.475                             0.506              0.504        
   2                         125                   9.742                                                                             9.464                                                                           0.458                             0.468               0.28        
   3                         112                   9.921                                                                             9.449                                                                           0.481                             0.476              0.284        
   4                         49                    10.299                                                                            10.26                                                                           0.471                             0.479              0.209        
  Lymphovascular invasion                                                                   0.443                                                                            0.871                                                            0.936              0.961              0.536
   Yes                       91                    9.846                                                                             9.661                                                                           0.498                              0.52              0.285        
   No                        217                   9.903                                                                             9.464                                                                           0.48                              0.497              0.282        
  Mucinous                                                                                 \<0.001                                                                          \<0.001                                                          \<0.001            \<0.001            \<0.001
   Yes                       39                     8.77                                                                             6.125                                                                           0.544                             0.579              0.561        
   No                        311                   10.102                                                                            9.919                                                                           0.452                             0.468              0.239        

Abbreviations: CIMP=CpG island methylator phenotype; MSI=microsatellite instability; TCGA=The Cancer Genome Atlas.

*P*-values obtained by Mann--Whitney *U*-test if variable is dichotomous or Kruskal--Wallis test if \>2 variables.

###### Univariate Cox regression analysis and multivariate Cox regression analysis after multiple imputations of MDACC ATTACC cohort for PFS

  **Variable**                                            **Hazard ratio (95% CI)**   ***P***
  ------------------------------------------------------ --------------------------- ---------
  **Univariate analysis**                                                            
  CIMP-high                                                   2.38 (1.47--3.85)       0.00043
  Right-sided                                                 1.56 (1.01--2.41)        0.043
  *BRAF* mutant                                               2.14 (1.26--3.65)        0.005
  *NRAS* mutant                                               2.12 (1.23--3.65)        0.007
  *PIK3CA* mutant                                             0.97 (0.53--1.77)        0.92
  PTEN loss                                                   1.07 (0.57--2.03)        0.828
  MSI-high                                                    1.27 (0.39--4.12)        0.691
  Non-white                                                   1.24 (0.78--1.96)        0.362
  Age                                                         0.98 (0.96--1.00)        0.055
  Male sex                                                    1.07 (0.72--1.60)        0.727
  Prior bevacizumab before EGFR                               1.26 (0.76--2.07)        0.368
  EGFR monotherapy                                            1.49 (0.75--2.97)        0.26
  No. of prior chemo regimens                                 1.18 (0.91--1.53)        0.203
  **Multivariate analysis**[a](#t3-fn2){ref-type="fn"}                               
  CIMP-high                                                   2.00 (1.11--3.64)        0.022
  Right-sided                                                 1.43 (0.86--2.36)        0.167
  *BRAF* mutant                                               2.50 (1.22--5.13)        0.012
  *NRAS* mutant                                               2.27 (1.25--4.13)        0.007

Abbreviations: ATTACC=Assessment of Targeted Therapies Against Colorectal Cancer; CI-confidence interval; CIMP=CpG island methylator phenotype; MDACC=MD Anderson Cancer Center; PFS=progression-free survival.

Adjusted for the number of prior regimens, age, prior bevacizumab, and use of anti-EGFR as monotherapy or in combination with chemotherapy.
